We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Slaps Import Ban on Fifth Ranbaxy Facility
Ranbaxy’s regulatory woes deepened last week as the FDA on Jan. 23 prohibited its Toansa, India, plant from making and distributing active pharmaceutical ingredients for U.S. products.